An Integrative Multi-Omics Analysis of The Molecular Links between Aging and Aggressiveness in Thyroid Cancers

Abstract

Aging modifies risk in all cancers, but age is used as a clinical staging criterion uniquely in thyroid cancer (TC). The molecular drivers of age-dependent TC onset and aggressiveness remain poorly understood. We applied an integrative, multi-omics data analysis approach to characterize these signatures. Our analysis reveals that aging, independent of BRAF V600E mutational status, drives a significant accumulation of aggressiveness-related markers and poorer survival outcomes, most noticeably at age 55 and over. We identified that chromosomal alterations in loci 1p/1q as aging-associated drivers of aggressiveness, and that depleted infiltration with tumor surveillant CD8+T and follicular helper T cells, dysregulation of proteostasis- and senescence-related processes, and ERK1/2 signaling cascade are key features of the aging thyroid and TC onset/progression and aggressiveness in aging patients but not in young individuals. A panel of 23 genes, including those related to cell division such as CENPF, ERCC6L, and the kinases MELK and NEK2, were identified and rigorously characterized as aging-dependent and aggressiveness-specific markers. These genes effectively stratified patients into aggressive clusters with distinct phenotypic enrichment and genomic/transcriptomic profiles. This panel also showed excellent performance in predicting metastasis stage, BRAF V600E , TERT promoter mutation, and survival outcomes and was superior to the American Thyroid Association (ATA) methodology in predicting aggressiveness risk. Our analysis established clinically relevant biomarkers for TC aggressiveness factoring in aging as an important component.

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer

“…Aging is a well-known risk factor for various tumors, as it results in reduced cell proliferation, homing, and differentiation processes (Feng et al 2023 ; Hu et al 2022 ; Feng et al 2020 ). These abnormalities in the human body contribute to the promotion and development of tumors (Ruiz et al 2023 ). Hence, it is crucial to identify the genetic intersection between aging and tumors and subsequently intervene in this process.…”

Comprehensive analysis of PPP4C’s impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics

“…By rigorously analyzing high-throughput RNA sequencing data, it is possible to support initiatives in personalized treatment and precision medicine. This includes identifying emerging prognostic markers and therapeutic targets, elucidating principal genes that affect the immune infiltration status of patients, and delineating the molecular pathways that promote the progression of LUAD ( 24 , 25 ). These objectives can be fulfilled through the application of differential expression analysis and functional enrichment studies ( 26 ).…”

A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing

“…Papillary thyroid carcinoma (PTC) account for almost 80% of thyroid cancer cases, and its incidence is rapidly increasing in worldwide ( Haugen et al, 2016 ; Siegel et al, 2022 ). Although most thyroid cancers have a good prognosis and can be treated surgically, there is still a lack of standard treatment for those highly aggressive and poorly differentiated tumors, which are prone to progression to advanced tumors ( Giannini et al, 2019 ; Ruiz et al, 2023 ). There is a rather part of patients not sensitive to radioactive iodine (RAI) ablation and thyroid stimulating hormone (TSH) suppression treatment ( Tiedje and Fagin, 2020 ).…”